Top

International Journal of Clinical Oncology

Published in:

23-05-2022 | NSCLC | Review Article

Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis

Authors: Shaofang Feng, Huiwen Mu, Rong Hou, Yunxin Liu, Jianjun Zou, Zheng Zhao, Yubing Zhu

Published in: International Journal of Clinical Oncology | Issue 7/2022

Abstract

The prognostic value of myosteatosis has been widely investigated in lung cancer, yet conclusions remain controversial. The purpose of this meta-analysis was to illuminate this issue. Medline, Embase, Cochrane Library and Web of Science Core Collection online databases were systematically searched from inception to 24 September 2021. Newcastle–Ottawa Scale tool was applied to evaluate the quality of included studies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were used to examine prognostic value of myosteatosis. Subgroup analysis and sensitivity analysis were conducted to assess heterogeneity and stability of results. A total of 484 articles were screened from which 9 eligible studies involving 1667 patients were enrolled in this meta-analysis. Lung cancer patients with myosteatosis had significantly worse OS than patients without myosteatosis (HR 1.10, 95% CI 1.05–1.16, P < 0.001), both in six multivariate analysis (HR 1.46, 95% CI 1.16–1.85, P = 0.001) and in three univariate analysis (HR 1.08, 95% CI 1.03–1.14, P = 0.003). Pooled data from five studies using multivariate survival analysis also showed that patients with myosteatosis had a statistically significant unfavorable PFS (HR = 1.27, 95% CI 1.00–1.62, P = 0.049). Sensitivity analysis showed the result for OS was stable. But for PFS, the result was not robust. Myosteatosis might serve as an independent indicator of unfavorable survival outcomes for OS and PFS in lung cancer patients. Further studies are needed to confirm our results.

Thai AA, Solomon BJ, Sequist LV et al (2021) Lung cancer. Lancet 398(10299):535–554. https://doi.org/10.1016/S0140-6736(21)00312-3CrossRefPubMed

Woodard GA, Jones KD, Jablons DM (2016) Lung cancer staging and prognosis. Cancer Treat Res 170:47–75. https://doi.org/10.1007/978-3-319-40389-2_3CrossRefPubMed

Wang A, Wang HY, Liu Y et al (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol 41(4):450–456. https://doi.org/10.1016/j.ejso.2015.01.020CrossRefPubMed

Simmons CP, Koinis F, Fallon MT et al (2015) Prognosis in advanced lung cancer–a prospective study examining key clinicopathological factors. Lung Cancer 88(3):304–309. https://doi.org/10.1016/j.lungcan.2015.03.020CrossRefPubMed

Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539–1547. https://doi.org/10.1200/jco.2012.45.2722CrossRefPubMed

Grønberg BH, Sjøblom B, Wentzel-Larsen T et al (2019) A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. Eur J Clin Nutr 73(7):1069–1076. https://doi.org/10.1038/s41430-018-0325-5CrossRefPubMed

Amini B, Boyle SP, Boutin RD et al (2019) Approaches to assessment of muscle mass and myosteatosis on computed tomography: a systematic review. J Gerontol A Biol Sci Med Sci 74(10):1671–1678. https://doi.org/10.1093/gerona/glz034CrossRefPubMedPubMedCentral

Goodpaster BH, Carlson CL, Visser M et al (2001) Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol 90(6):2157–2165. https://doi.org/10.1152/jappl.2001.90.6.2157CrossRefPubMed

Correa-de-Araujo R, Addison O, Miljkovic I et al (2020) Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the national institute on aging. Front Physiol 11:963. https://doi.org/10.3389/fphys.2020.00963CrossRefPubMedPubMedCentral

10.

Goodpaster BH, Kelley DE, Thaete FL et al (2000) Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89(1):104–110. https://doi.org/10.1152/jappl.2000.89.1.104CrossRefPubMed

11.

Okugawa Y, Orcid Id, Toiyama Y et al (2018) Clinical impact of muscle quantity and quality in colorectal cancer patients: a propensity score matching analysis. JPEN J Parenter Enteral Nutr 42(8):1322–1333. https://doi.org/10.1002/jpen.1171CrossRefPubMed

12.

Pozzuto L, Silveira MN, Mendes MCS et al (2021) Myosteatosis differentially affects the prognosis of non-metastatic colon and rectal cancer patients: an exploratory study. Front Oncol 11:762444. https://doi.org/10.3389/fonc.2021.762444CrossRefPubMedPubMedCentral

13.

Lee CM, Kang J (2020) Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 11(5):1270–1282. https://doi.org/10.1002/jcsm.12575CrossRefPubMedPubMedCentral

14.

Aleixo GFP, Orcid Id, Williams GR et al (2019) Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review. Breast Cancer Res Treat 177(3):569–579. https://doi.org/10.1007/s10549-019-05352-3CrossRefPubMed

15.

McSharry V, Mullee A, McCann L et al (2020) The impact of sarcopenia and low muscle attenuation on overall survival in epithelial ovarian cancer: a systematic review and meta-analysis. Ann Surg Oncol 27(9):3553–3564. https://doi.org/10.1245/s10434-020-08382-0CrossRefPubMed

16.

Cortellini A, Orcid Id, Palumbo P et al (2018) Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer 9(12):1623–1630. https://doi.org/10.1111/1759-7714.12870CrossRefPubMedPubMedCentral

17.

Bowden JCS, Williams LJ, Simms A et al (2017) Prediction of 90 day and overall survival after chemoradiotherapy for lung cancer: role of performance status and body composition. Clin Oncol 29(9):576–584. https://doi.org/10.1016/j.clon.2017.06.005CrossRef

18.

Nattenmüller J, Wochner R, Muley T et al (2017) Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients. PLoS ONE 12(1):e0169136. https://doi.org/10.1371/journal.pone.0169136CrossRefPubMedPubMedCentral

19.

Nishioka N, Naito T, Orcid Id et al (2021) Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med 10(1):247–256. https://doi.org/10.1002/cam4.3631CrossRefPubMed

20.

Kiss N, Orcid Id, Beraldo J et al (2019) Early skeletal muscle loss in non-small cell lung cancer patients receiving chemoradiation and relationship to survival. Support Care Cancer 27(7):2657–2664. https://doi.org/10.1007/s00520-018-4563-9CrossRefPubMed

21.

Minami S, Ihara S, Nishimatsu K et al (2019) Low body mass index is an independent prognostic factor in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitor. World J Oncol 10(6):187–198. https://doi.org/10.14740/wjon1244CrossRefPubMedPubMedCentral

22.

Minami S, Ihara S, Komuta K (2020) Sarcopenia and visceral adiposity are not independent prognostic markers for extensive disease of small-cell lung cancer: a single-centered retrospective cohort study. World J Oncol 11(4):139–149. https://doi.org/10.14740/wjon1289CrossRefPubMedPubMedCentral

23.

Minami S, Ihara S, Tanaka T et al (2020) Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer. World J Oncol 11(1):9–22. https://doi.org/10.14740/wjon1225CrossRefPubMedPubMedCentral

24.

Abbass T, Dolan RD, MacLeod N et al (2020) Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer. Clin Nutr ESPEN 40:349–356. https://doi.org/10.1016/j.clnesp.2020.08.003CrossRefPubMed

25.

Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(16):1745–6215. https://doi.org/10.1186/1745-6215-8-16CrossRef

26.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

27.

Relli V, Trerotola M, Guerra E et al (2019) Abandoning the Notion of Non-Small Cell Lung Cancer. Trends Mol Med 25(7):585–594. https://doi.org/10.1016/j.molmed.2019.04.012CrossRefPubMed

28.

Beadsmoore CJ, Screaton NJ (2003) Classification, staging and prognosis of lung cancer. Eur J Radiol 45(1):8–17. https://doi.org/10.1016/s0720-048x(02)00287-5CrossRefPubMed

29.

Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584CrossRefPubMed

30.

Choi S, Park J (2020) Surgical outcomes and prognosis of non-small-cell lung cancer in patients with chronic lung diseases: a retrospective analysis. Eur J Cardiothorac Surg 58(2):357–364. https://doi.org/10.1093/ejcts/ezaa060CrossRefPubMed

31.

Clausen MM, Langer SW (2019) Improving the prognosis for lung cancer patients. Acta Oncol 58(8):1077–1078. https://doi.org/10.1080/0284186X.2019.1632477CrossRefPubMed

32.

Aleixo GFP, Shachar SS, Nyrop KA et al (2020) Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol 145:102839. https://doi.org/10.1016/j.critrevonc.2019.102839CrossRefPubMed

33.

Ahn H, Kim DW, Ko Y et al (2021) Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia. Ageing Res Rev 70:101398. https://doi.org/10.1016/j.arr.2021.101398CrossRefPubMed

34.

Miljkovic I, Cauley JA, Wang PY et al (2013) Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes. Obesity 21(10):2118–2125. https://doi.org/10.1002/oby.20346CrossRefPubMed

35.

Kovalik JP, Slentz D, Stevens RD et al (2011) Metabolic remodeling of human skeletal myocytes by cocultured adipocytes depends on the lipolytic state of the system. Diabetes 60(7):1882–1893. https://doi.org/10.2337/db10-0427CrossRefPubMedPubMedCentral

36.

Dev R, Bruera E, Dalal S (2018) Insulin resistance and body composition in cancer patients. Ann Oncol 29(2):18–26. https://doi.org/10.1093/annonc/mdx815CrossRef

37.

Souza NC, Gonzalez MC, Martucci RB et al (2020) Frailty is associated with myosteatosis in obese patients with colorectal cancer. Clin Nutr 39(2):484–491. https://doi.org/10.1016/j.clnu.2019.02.026CrossRefPubMed

38.

Dodson S, Baracos VE, Jatoi A et al (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279. https://doi.org/10.1146/annurev-med-061509-131248CrossRefPubMed

39.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. https://doi.org/10.1038/nature01322CrossRefPubMedPubMedCentral

40.

Yamashita S, Iwahashi Y, Miyai H et al (2020) Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer. Sci Rep 10(1):22146. https://doi.org/10.1038/s41598-020-79340-9CrossRefPubMedPubMedCentral

41.

Miljkovic I, Vella CA, Allison M (2021) Computed tomography-derived myosteatosis and metabolic disorders. Diabetes Metab J 45(4):482–491. https://doi.org/10.4093/dmj.2020.0277CrossRefPubMedPubMedCentral

42.

Xiao J, Caan BJ, Weltzien E et al (2018) Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. J Cachexia Sarcopenia Muscle 9(4):654–663. https://doi.org/10.1002/jcsm.12301CrossRefPubMedPubMedCentral

43.

Kim EY, Kim YS, Park I et al (2015) Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer. J Thorac Oncol 10(12):1795–1799. https://doi.org/10.1097/jto.0000000000000690CrossRefPubMed

44.

Yang M, Shen Y, Tan L et al (2019) Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest 156(1):101–111. https://doi.org/10.1016/j.chest.2019.04.115CrossRefPubMed

45.

Pamoukdjian F, Bouillet T, Lévy V et al (2018) Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr 37(4):1101–1113. https://doi.org/10.1016/j.clnu.2017.07.010CrossRefPubMed

46.

Stretch C, Aubin JM, Mickiewicz B et al (2018) Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. PLoS ONE 13(5):e0196235. https://doi.org/10.1371/journal.pone.0196235CrossRefPubMedPubMedCentral

Title: Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis
Authors: Shaofang Feng
Huiwen Mu
Rong Hou
Yunxin Liu
Jianjun Zou
Zheng Zhao
Yubing Zhu
Publication date: 23-05-2022
Publisher: Springer Nature Singapore
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
SCLC
Lung Cancer
SCLC
Published in: International Journal of Clinical Oncology / Issue 7/2022
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-022-02181-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2022

Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma

Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801

The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis

Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia

Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma

Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer